ODE V Deputy Director Bowen Leaves FDA For McNeil Position
This article was originally published in The Rose Sheet
Executive Summary
FDA Center for Drug Evaluation & Research Office of Drug Evaluation V Deputy Director Debra Bowen, MD, has left the agency to become McNeil's VP-Clinical Research.
You may also be interested in...
ODE V
Jonca Bull, MD, appointed deputy director, FDA Office of Drug Evaluation V, responsible for OTCs. Bull will report to ODE V Director Robert DeLap, MD/PhD, effective July 30. Debra Bowen, MD, left the position early this year to join McNeil Consumer Healthcare as VP-clinical research (1"The Rose Sheet" Jan. 3, p. 13). Currently acting director of the Office of Women's Health, Bull previously worked in the Office of the Commissioner as a special assistant and medical advisor to the deputy commissioner for operations. She joined FDA in 1994
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program